DESTINY-Breast11 and Surrogate Endpoints

<p>Thoughts on using pCR as a surrogate endpoint</p><p><br></p><p>DESTINY-Breast11: <a href="https://pubmed.ncbi.nlm.nih.gov/41130363/">https://pubmed.ncbi.nlm.nih.gov/41130363/</a></p><p><br></p><p>Clinical Cancer Research publication on pCR, EFS and OS: <a href="https://aacrjournals.org/clincancerres/article/26/12/2838/82378/Pathologic-Complete-Response-after-Neoadjuvant">https://aacrjournals.org/clincancerres/article/26/12/2838/82378/Pathologic-Complete-Response-after-Neoadjuvant</a></p><p>BMJ publication on pCR, EFS and OS: <a href="https://www.bmj.com/content/375/bmj-2021-066381">https://www.bmj.com/content/375/bmj-2021-066381</a></p><p>FDA-sponsored analysis: <a href="https://pubmed.ncbi.nlm.nih.gov/24529560/">https://pubmed.ncbi.nlm.nih.gov/24529560/</a></p><p>KATHERINE trial: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1814017">https://www.nejm.org/doi/full/10.1056/NEJMoa1814017</a></p>